Myasthenia Gravis Market Expected to Increase with a CAGR of Around 6.15% during the Study Period [2017-2030], States DelveInsight
- The increasing prevalence and promising emerging therapies with a new mechanism of action will fuel the Myasthenia Gravis market during the forecasted period of 2020–2030.
LAS VEGAS, June 17, 2021 /PRNewswire/ -- DelveInsight's "Myasthenia Gravis Market" report provides a thorough comprehension of the Myasthenia Gravis historical and forecasted epidemiology and the Myasthenia Gravis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Myasthenia Gravis market report also proffers an analysis of the current Myasthenia Gravis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the necessary takeaways from the Myasthenia Gravis Market Research Report
- Several key pharmaceutical companies such as Alexion Pharmaceuticals, Valeant Pharmaceuticals, Astellas Pharma, Mitsubishi Tanabe Pharma, Catalyst Pharmaceuticals, UCB Pharma, Novartis, CSL Behring, Ra Pharmaceuticals, Argenx, Takeda, and others are explicitly designing therapies to target generalized as well as antibody-positive Myasthenia Gravis treatment options.
- The Myasthenia Gravis pipeline is crowded with several potential therapies such as Rozanolixizumab, Ravulizumab, Efgartigimod, Zilucoplan, Firdapse, Hizentra, IMVT-1401, M281, TAK-079, and others.
- Anticipated approval of novel monoclonal antibodies has created a robust Myasthenia Gravis market growth during the forecast period. Most of these are proven successful in their clinical studies and have been allotted with designations, and other registry authorities support easing the Myasthenia Gravis market entrance.
- The increase in prevalence, approval of monoclonal antibodies, and the robust pipeline are significant factors driving the Myasthenia Gravis market. Nevertheless, the high treatment cost and lack of awareness of the disease are major hindrances in the Myasthenia Gravis market growth.
For further information on Market Impact by Therapies, visit: Myasthenia Gravis Drugs Market Analysis
Myasthenia Gravis (MG) is an autoimmune disease that is characterized by muscle weakness and fatigue. Generalized Myasthenia Gravis is a more severe form of Myasthenia Gravis (MG) that may experience weakness in other muscle groups.
As per DelveInsight's estimates, the total prevalent cases of Myasthenia Gravis in the 7MM were 132,841 in 2020. Also, it has been observed that Myasthenia Gravis is more prominent in females as compared to males.
The Myasthenia Gravis Market Analysis Report provides historical as well as forecasted epidemiological analysis segmented into:
- Total Prevalent Cases of Myasthenia Gravis
- Gender-Specific Prevalent Cases of Myasthenia Gravis
- Severity Specific Diagnosed Prevalent Cases of Myasthenia Gravis
- Autoantibodies Specific Diagnosed Prevalent Cases of Myasthenia Gravis
Get a complete epidemiological segmentation @ Myasthenia Gravis Epidemiological Analysis
Myasthenia Gravis Treatment Market
The therapeutic market size of Myasthenia Gravis in the United States is mainly accounted by symptomatic treatments, including acetylcholinesterase inhibitors (Mestinon), short-term immunosuppressants (corticosteroids), long-term immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid-acting short-term immunomodulators (intravenous immunoglobulin, plasma exchange), and long-term immunomodulatory procedures (thymectomy).
Rituxan (Genentech) has been shown to reverse specific, Myasthenia Gravis-like symptoms. Azathioprine acts more slowly than corticosteroids, producing improvement after 3–6 months, and usually has few side effects. However, occasionally it can produce serious side effects. Cyclophosphamide is a DNA-alkylating drug and nonspecific cell-cycle inhibitor. This drug is effective against Myasthenia Gravis, but it is not much used because it has many potentially serious side effects. Plasma Exchange is commonly used in severe acute exacerbation of the disease to achieve temporary improvement or as a method of optimizing Myasthenia Gravis control before surgery.
The Myasthenia Gravis market impetus has begun with Soliris (Eculizumab) (Alexion Pharmaceuticals), which got approval for Myasthenia Gravis treatment in 2017 as the first C5 inhibitor, a component of the complement cascade. This monoclonal antibody (MAB) is used for preventing acetylcholine receptor antibodies from affecting muscle cells and is also helpful for patients' resistance to the other available therapies.
The current advancement in the Myasthenia Gravis treatment process and increasing prevalence are the major market drivers of the Myasthenia Gravis market. Additionally, the current market is expected to change with the emerging therapies, which presently comprise biologics and molecules with new mechanisms of action. The approval of Soliris and the relevant pathway identification to target the disease laid the future to a more significant number of therapies in this direction.
Scope of the Myasthenia Gravis Market Insight Report
- Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
- Myasthenia Gravis Markets Segmentation: By Geographies and By Myasthenia Gravis Therapies (Historical and Forecasted, Current and Upcoming)
- Dominant Market Companies investigating its candidates for Myasthenia Gravis: Alexion Pharmaceuticals, Valeant Pharmaceuticals, Astellas Pharma, Mitsubishi Tanabe Pharma, UCB Pharma, Novartis, Catalyst Pharmaceuticals, CSL Behring, Ra Pharmaceuticals, Argenx, Takeda, and several others.
- Analysis: Comparative and conjoint analysis of emerging therapies.
- Case Studies
- KOL's Views
- Analyst's View
Request for a Webex demo of the report @ Myasthenia Gravis Therapeutics Market
Table of Contents
1 | Myasthenia Gravis Key Insights |
2 | Myasthenia Gravis Market Overview at a Glance |
3 | Executive Summary of Myasthenia Gravis |
4 | Organizations |
5 | Myasthenia Gravis Disease Overview |
6 | Myasthenia Gravis Epidemiology and Patient Population |
6.1 | The United States |
6.2 | EU5 Countries |
6.2.1 | Germany |
6.2.2 | France |
6.2.3 | Italy |
6.2.4 | Spain |
6.2.5 | The United Kingdom |
6.3 | Japan |
7 | Current Myasthenia Gravis Treatment Practices |
8 | Myasthenia Gravis Unmet Needs |
9 | Myasthenia Gravis Marketed drugs |
9.1 | Soliris: Alexion Pharmaceuticals |
9.2 | Mestinon: Valeant Pharmaceuticals |
9.3 | Prograf: Astellas Pharma |
9.4 | Venoglobulin IH: Mitsubishi Tanabe Pharma |
10 | Myasthenia Gravis Emerging Therapies |
10.1 | Firdapse: Catalyst Pharmaceuticals |
10.2 | Hizentra: CSL Behring |
10.3 | Zilucoplan: Ra Pharmaceuticals |
10.4 | Efgartigimod: Argenx |
10.5 | TAK-079: Takeda |
11 | Myasthenia Gravis: 7MM Market Analysis |
11.1 | The United States Myasthenia Gravis Market Size |
11.2 | EU-5 Myasthenia Gravis Market Size |
11.2.1 | Germany Market Size |
11.2.2 | France Market Size |
11.2.3 | Italy Market Size |
11.2.4 | Spain Market Size |
11.2.5 | The United Kingdom Market Size |
11.3 | Japan Myasthenia Gravis Market Size |
12 | Myasthenia Gravis Market Drivers |
13 | Myasthenia Gravis Market Barriers |
14 | Myasthenia Gravis Market Access and Reimbursement |
15 | SWOT Analysis |
16 | Case studies |
17 | KOL Views |
18 | Appendix |
19 | Report Methodology |
20 | DelveInsight Capabilities |
21 | Disclaimer |
22 | About DelveInsight |
Browse full report with detailed TOC with charts, figures, tables @ Myasthenia Gravis Diagnostics Market Report
View Related Reports
DelveInsight's Myasthenia Gravis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Myasthenia Gravis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Myasthenia Gravis Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across
Myasthenia Gravis Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020 " report by DelveInsight offers comprehensive insights on marketed and Phase III products for Myasthenia Gravis.
- Generalized Myasthenia Gravis Market
DelveInsight' s Generalized Myasthenia Gravis (gMG) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
- Generalized Myasthenia Gravis Pipeline
Generalized Myasthenia Gravis (gMG) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Generalized Myasthenia Gravis (gMG) market.
Related Posts
- Endoscopy Fluid Management Systems Growth Factors in the MedTech market
- Adult-onset Still's Disease treatment market
For ASCO updates, browse here:-
- Cholangiocarcinoma Highlights: ASCO 2021
- Sarcoma Highlights: ASCO 2021
- Esophageal Squamous Cell Carcinoma Highlights: ASCO 2021
- Breast Cancer Highlights - ASCO 2021
- Pancreatic Cancer Highlights: ASCO 2021
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Services with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
Share this article